Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.

Por A'Hern, R. P., Smith, I. E., Ebbs, S. R.
Publicado em 1993

Childhood T-cell lymphoblastic lymphoma--does early resolution of mediastinal mass predict for final outcome? The United Kingdom Children's Cancer Study Group (UKCCSG).

Por Shepherd, S. F., A'Hern, R. P., Pinkerton, C. R.
Publicado em 1995

Does chemotherapy improve survival in advanced breast cancer? A statistical overview.

Por A'Hern, R. P., Ebbs, S. R., Baum, M. B.
Publicado em 1988

Was Young's syndrome caused by exposure to mercury in childhood?

Por Hendry, W F, A'Hern, R P, Cole, P J
Publicado em 1993

Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD).

Por Ling, P. J., A'Hern, R. P., Hardy, J. R.
Publicado em 1995

Postoperative radiotherapy and late mortality: evidence from the Cancer Research Campaign trial for early breast cancer.

Por Haybittle, J. L., Brinkley, D., Houghton, J., A'Hern, R. P., Baum, M.
Publicado em 1989

Psychological effects of being offered choice of surgery for breast cancer.

Por Fallowfield, L. J., Hall, A., Maguire, P., Baum, M., A'Hern, R. P.
Publicado em 1994

Breast cancer, prostaglandins and patient survival.

Por Bennett, A., Stamford, I. F., Berstock, D. A., Dische, F., Singh, L., A'Hern, R. P.
Publicado em 1989

Duct carcinoma in situ: predictors of local recurrence and progression in patients treated by surgery alone.

Por Price, P., Sinnett, H. D., Gusterson, B., Walsh, G., A'Hern, R. P., McKinna, J. A.
Publicado em 1990

Platinum-Taxol non-cross resistance in epithelial ovarian cancer.

Por Gore, M. E., Preston, N., A'Hern, R. P., Hill, C., Mitchell, P., Chang, J., Nicolson, M.
Publicado em 1995

Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer.

Por Newby, J. C., A'Hern, R. P., Leek, R. D., Smith, I. E., Harris, A. L., Dowsett, M.
Publicado em 1995

A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma

Por Morris, S L, Low, S H, A'Hern, R P, Eisen, T G, Gore, M E, Nutting, C M, Harrington, K J
Publicado em 2004

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients w...

Por Johnston, S. R., Constenla, D. O., Moore, J., Atkinson, H., A'Hern, R. P., Dadian, G., Riches, P. G., Gore, M. E.
Publicado em 1998

Head and neck sarcomas: prognostic factors and implications for treatment.

Por Eeles, R. A., Fisher, C., A'Hern, R. P., Robinson, M., Rhys-Evans, P., Henk, J. M., Archer, D., Harmer, C. L.
Publicado em 1993

Proliferation in human bladder carcinoma measured by Ki-67 antibody labelling: its potential clinical importance.

Por Bush, C., Price, P., Norton, J., Parkins, C. S., Bailey, M. J., Boyd, J., Jones, C. R., A'Hern, R. P., Horwich, A.
Publicado em 1991

Hormone replacement therapy and survival after surgery for ovarian cancer.

Por Eeles, R A, Tan, S, Wiltshaw, E, Fryatt, I, A'Hern, R P, Shepherd, J H, Harmer, C L, Blake, P R, Chilvers, C E
Publicado em 1991

Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer

Por Kirby, A M, A'hern, R P, D'ambrosio, C, Tanay, M, Syrigos, K N, Rogers, S J, Box, C, Eccles, S A, Nutting, C M, Harrington, K J
Publicado em 2006

Chemotherapy for ovarian cancer--a consensus statement on standard practice.

Por Adams, M., A'Hern, R. P., Calvert, A. H., Carmichael, J., Clark, P. I., Coleman, R. E., Earl, H. M., Gallagher, C. J., Ganesan, T. S., Gore, M. E., Graham, J. D., Harper, P. G., Jayson, G. C., Kaye, S. B., Ledermann, J. A., Osborne, R. J., Perren, T. J., Poole, C. J., Radford, J. A., Rustin, G. J., Slevin, M. L., Smyth, J. F., Thomas, H., Wilkinson, P. M.
Publicado em 1998